Erasca, Inc. Report issue

For profit Phase 1 Phase 2
Founded: San Diego CA United States (2018)

Organization Overview

First Clinical Trial
2020
NCT04670679
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Alternative names

Erasca, Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 7
  • # of Trial APIs: 11